CORCEPT THERAPEUTICS Business Summary

Corcept Therapeutics Inc. (CORT) is a commercial-stage biopharmaceutical company that generates revenue primarily through the sale of Korlym (mifepristone), its proprietary treatment for patients with Cushing’s syndrome. The company’s business model is centered on the discovery, development, and commercialization of selective cortisol modulators, operating through a single pharmaceutical product segment that targets severe endocrinologic, oncologic, metabolic, and neurologic disorders. Corcept maintains a dominant position in the hypercortisolism market, leveraging an extensive intellectual property portfolio of over 1,000 cortisol-modulating compounds to expand into indications such as platinum-resistant ovarian cancer, MASH, and amyotrophic lateral sclerosis (ALS). Its primary direct competitors include Recordati (Isturisa), Crinetics Pharmaceuticals (paltusotine), Teva Pharmaceuticals (generic Korlym), and Jazz Pharmaceuticals. Relative to these peers, Corcept is the established leader in the cortisol modulation niche, though it faces increasing pressure from generic entrants and emerging competitors in the endocrine space. The company was co-founded in 1998 by Dr. Joseph K. Belanoff and Dr. Alan Schatzberg, both prominent psychiatrists from Stanford University with deep expertise in cortisol research. The current leadership team is led by Dr. Belanoff as CEO and President, supported by Atabak Mokari as Chief Financial Officer, Hazel Hunt, Ph.D., as Chief Scientific Officer, and Joseph D. Lyon as Chief Accounting and Technology Officer. Other key executives include Sean Maduck, President of Corcept Endocrinology, and William Guyer, Chief Development Officer. Corcept is backed by major institutional investors including BlackRock, Vanguard, and Renaissance Technologies. Its Board of Directors features seasoned industry veterans such as Chairman James N. Wilson, former Amylin CEO Daniel Bradbury, and G. Leonard Baker, Jr. of Sutter Hill Ventures, providing significant strategic oversight in the biotechnology and specialty pharmaceutical sectors.